NanoViricides (NNVC) Stock Price & Analysis Today

NNVC

(NYSEAMERICAN)

NanoViricides, Inc.

$0.93-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

NanoViricides Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$0.91 - $0.94

52-Week High$2.23

52-Week Low$0.85

Open$0.94

Volume175.52K

Average Volume (3M)175.52K

Market Cap18.47M

Shares Outstanding19.85M

Price to Book (P/B)0.00

EV/EBITDA666798.85

50-Day MA$1.01

200-Day MA$1.32

52-Week Change-17.71%

Annual Dividend$0.00

Dividend Yield0.00%

Day's Range$0.91 - $0.94

52-Week High$2.23

52-Week Low$0.85

Open$0.94

Volume175.52K

Average Volume (3M)175.52K

Market Cap18.47M

Shares Outstanding19.85M

Price to Book (P/B)0.00

EV/EBITDA666798.85

50-Day MA$1.01

200-Day MA$1.32

52-Week Change-17.71%

Annual Dividend$0.00

Dividend Yield0.00%

About NanoViricides

Company overview, fundamentals, and corporate profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Frequently Asked Questions About NanoViricides

What is the current stock price for NNVC?

As of the latest trading session, NNVC stock trades at $0.93. The 52-week range is $0.85–$2.23, with a day range of $0.91–$0.94.

What is the P/E ratio for NNVC?

The P/E ratio (Price-to-Earnings) for NNVC is shown in the Key Statistics section. This valuation metric helps compare NanoViricides, Inc. to industry peers.

Does NNVC pay dividends?

NanoViricides does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for NNVC?

Analyst ratings and recommendations for NNVC are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of NNVC?

NanoViricides's market capitalization is $18.5M, classifying it as a micro-cap company. NanoViricides operates in the Healthcare sector within the Biotechnology industry.

NanoViricides (NNVC) Stock Price & Financial Analysis

NanoViricides Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About NanoViricides